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Introduction {#sec1}
============

Inflammation is a crucial protective response conserved in all multicellular organisms ([@bib36]). It entails activation of many cell types through several signaling pathways including nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3), resulting in release of cytokines and chemokines. Inflammation is tightly regulated and is effectively turned off when no longer needed ([@bib33], [@bib42]). Malfunction of the shutdown machinery might result in chronic inflammation, promoting pathologies such as inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease ([@bib34], [@bib32]). Although proper inflammatory response may suppress cancer ([@bib35]), chronic inflammation can promote tumor initiation and progression ([@bib4], [@bib45], [@bib18], [@bib48], [@bib3], [@bib20]). Notably, IBD patients carry an increased cancer risk ([@bib14]).

NF-κB transcription factors consist of different dimeric combinations of p50, p52, p65 (RelA), c-Rel, and RelB, binding DNA as either hetero- or homodimers ([@bib12]). Since only p65, c-Rel, and RelB contain transcriptional activation domains (TAD), dimers comprising these subunits can activate transcription while the others repress transcription unless they recruit specific co-activators ([@bib23], [@bib29]). Additionally, NF-κB regulates diverse processes such as apoptosis, cell proliferation, differentiation, and tumorigenesis ([@bib12], [@bib44]).

Eukaryotic DNA is packaged in nucleosomes consisting of four core histones (H2A, H2B, H3, and H4), which undergo many post-translational modifications (PTM) that control chromatin dynamics and transcription ([@bib6]). One such PTM is monoubiquitylation of mammalian histone H2B on lysine 120 (H2Bub1), executed primarily by the RNF20 (hBRE1)/RNF40 E3 ligase complex ([@bib24]).

H2Bub1 resides mainly downstream to transcription start sites (TSS), in preferential association with highly transcribed genes ([@bib37]). It participates in RNA polymerase II (RNA Pol II)-dependent transcription, cooperatively with the facilitates chromatin transcription (FACT) and polymerase-associated factor (PAF) complex ([@bib43]). H2Bub1 can also negatively regulate transcription and may contribute to heterochromatin silencing ([@bib63]). In HeLa cells, H2Bub1 modulates transcription of specific gene sets ([@bib51]): one subgroup, enriched in proto-oncogenes, is upregulated upon partial RNF20 depletion, while the other, including the p53 tumor suppressor, is downregulated. Furthermore, H2Bub1 impedes recruitment of TFIIS, a factor capable of relieving paused RNA Pol II ([@bib52]). Conversely, H2Bub1 upregulates other transcripts by favoring recruitment of the SWI/SNF chromatin remodeling complex ([@bib53]).

Notably, RNF20 displays tumor suppressor features ([@bib51]). Moreover, RNF20 and H2Bub1 are reduced in many cancers ([@bib46], [@bib9], [@bib19], [@bib59], [@bib57], [@bib60], [@bib2]). H2Bub1 levels are low in both embryonic and adult stem cells but increase during differentiation and may be a prerequisite for proper execution of the differentiation program ([@bib16], [@bib27]). Additionally, RNF20 and H2Bub1 are implicated in the DNA damage response, replication stress, and chromosomal stability ([@bib26], [@bib38], [@bib41], [@bib54], [@bib7], [@bib57]).

H2Bub1 is coupled to ongoing transcription ([@bib43], [@bib63]). Its modulation affects the transcriptional response to epidermal growth factor (EGF) ([@bib51]), estrogen ([@bib46], [@bib2]), interferon gamma ([@bib5]), and androgens ([@bib25]). We now report that RNF20 depletion, leading to decreased H2Bub1, augments the ability of the proinflammatory cytokine tumor necrosis factor alpha (TNF-α) to upregulate a panel of inflammation-associated genes. Importantly, mice with reduced RNF20 and H2Bub1 are predisposed to chronic colonic inflammation. Notably, colons of UC patients tend to underexpress *RNF20* and *RNF40* mRNA, in conjunction with H2Bub1 downregulation in both epithelial and stromal compartments. Moreover, RNF20-low mice succumb preferentially to inflammation-associated colorectal cancer (CRC) and their tumors exhibit reduced H2Bub1, as observed also in human CRC. Hence, attenuation of RNF20 and H2Bub1 may facilitate the emergence of chronic inflammation and subsequent cancer.

Results {#sec2}
=======

RNF20 Restricts NF-κB Target Gene Transcription in Response to TNF-α {#sec2.1}
--------------------------------------------------------------------

To explore links between H2Bub1 and inflammation, we monitored H2Bub1 levels in cells exposed to TNF-α, employing non-transformed human mammary epithelial MCF10A cells. TNF-α downregulated transiently H2Bub1, both globally ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A) and at promoters and bodies of several cytokine genes ([Figure S1](#mmc1){ref-type="supplementary-material"}B). This was not due to a decrease in *RNF20* mRNA ([Figure S1](#mmc1){ref-type="supplementary-material"}C) or protein ([Figure 1](#fig1){ref-type="fig"}A). As expected, RNF20 knockdown caused substantial H2Bub1 loss ([Figure S1](#mmc1){ref-type="supplementary-material"}A, siRNF20).

TNF-α transactivated many genes including *IL8* and *IL6*, as revealed by analysis of heterogeneous nuclear RNA (hnRNA) corresponding to primary transcripts ([Figure 1](#fig1){ref-type="fig"}B). Notably, RNF20 knockdown ([Figure S1](#mmc1){ref-type="supplementary-material"}C) accelerated and prolonged this effect ([Figure 1](#fig1){ref-type="fig"}B), upregulating mature cytokine mRNA ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). In contrast, RNF20 knockdown downregulated the non-inflammatory genes *p53* and *Bcl2* ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Hence RNF20, presumably through H2Bub1, restricts the activation of a set of inflammation-associated genes. Notably, knockdown of additional H2Bub1 machinery genes (RNF40 and hRAD6A) elicited similar effects ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). Augmented cytokine gene expression was seen with three different RNF20 small interfering RNA (siRNA) oligos ([Figure S1](#mmc1){ref-type="supplementary-material"}I), ruling out off-target effects.

In non-stimulated state, promoter regions of several proinflammatory cytokine genes are decorated with H3K9me3 ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}J); this heterochromatin mark decreased transiently upon TNF-α exposure, concomitantly with the transcription wave ([Figure S1](#mmc1){ref-type="supplementary-material"}J). Remarkably, H3K9me3 was selectively depleted from such promoters upon RNF20 knockdown, along with increased binding of paused (Ser5-phosphorylated) RNA Pol II ([Figure 1](#fig1){ref-type="fig"}D); this may underpin the accelerated transcriptional response to inflammatory stimuli ([Figure 1](#fig1){ref-type="fig"}B).

RNF20 Favors p50 Binding and Disfavors p65 Binding to κB Sites {#sec2.2}
--------------------------------------------------------------

Transcriptional induction of cytokine genes by TNF-α is largely mediated through NF-κB activation ([@bib21], [@bib3]). Indeed, p65 depletion practically ablated the response ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The canonical NF-κB response to TNF-α employs primarily p65/p50 dimers ([@bib22]). Interestingly, rather than compromising *IL8* and *CXCL1* expression, p50 knockdown upregulated those genes ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Hence, in this system, repressive p50 homodimers may outweigh activating p65-containing dimers, while partial p50 depletion alleviates repression and promotes transcription by favoring p65-containing dimers. We therefore employed chromatin immunoprecipitation (ChIP)-qPCR to assess the association of p65 and p50 with relevant κB sites. In non-treated cells, p65 occupancy was very low, just above a control gene (*p21/CDKN1A)* lacking κB sites ([Figure 2](#fig2){ref-type="fig"}A). TNF-α increased p65 occupancy, which was further augmented by RNF20 depletion in *IL8* and *CXCL1*. RNF20 knockdown did not affect TNF-α-induced IκB degradation ([Figure S2](#mmc1){ref-type="supplementary-material"}C) or p65 nuclear translocation ([Figure S2](#mmc1){ref-type="supplementary-material"}D). However, it reduced basal and TNF-α-induced p50 binding, modestly in *IL6* and more strongly in *IL8* ([Figure 2](#fig2){ref-type="fig"}B), and affected differentially the global recruitment of NF-κB subunits to chromatin upon TNF-α treatment, favoring p65 over p50 ([Figure 2](#fig2){ref-type="fig"}C).

We next performed sequential ChIP ("re-ChIP"), reacting the chromatin first with anti-p65 and then anti-p50 antibodies. As expected, TNF-α increased the abundance of putative p65-p50 heterodimers ([Figure 2](#fig2){ref-type="fig"}D). Notably, this was further moderately augmented by RNF20 knockdown. Thus, RNF20 depletion alters the ratio between chromatin-associated NF-κB subunits in favor of p65, facilitating transcriptional activation.

RNF20 Downregulation Augments the TNF-α Response in Mouse Colonocytes, Intestinal Organoids, and Innate Immune Cells {#sec2.3}
--------------------------------------------------------------------------------------------------------------------

To extend our observations to non-cancerous mouse epithelial cells, young adult mouse colonocytes (YAMC) ([@bib62]) cells were employed. As in MCF10A cells, TNF-α elicited a rapid transient decrease in H2Bub1 also in YAMC cells ([Figure 3](#fig3){ref-type="fig"}A). As expected, RNF20 KD ([Figure S3](#mmc1){ref-type="supplementary-material"}A) diminished H2Bub1 ([Figure 3](#fig3){ref-type="fig"}A). Notably, it augmented the induction of *IL6* and *KC* (a mouse homolog of *IL8*) ([Figure 3](#fig3){ref-type="fig"}B).

To investigate whether RNF20 affects inflammation in vivo, we attempted to generate RNF20 knockout mice utilizing embryonic stem cells carrying a gene trap insertion within the *RNF20* gene (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}); the insert is located between exons 17 and 18, and the predicted 97 kDa protein should lack the C′ terminal RING domain. Such truncated protein was undetectable ([Figure S3](#mmc1){ref-type="supplementary-material"}B), suggesting its intrinsic instability. Our attempts to obtain viable homozygous knockout progeny failed, owing to preimplantation embryonic lethality.

Heterozygous RNF20^+/−^ mice were viable and appeared normal. We derived small intestinal 3D organoid cultures ([@bib47]) from wild-type (WT) and RNF20^+/−^ mice. As expected, RNF20^+/−^ organoids had less *RNF20* mRNA and H2Bub1 than WT organoids ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C). Importantly, TNF-α elicited a rapid decrease in H2Bub1 ([Figure 3](#fig3){ref-type="fig"}C), and NF-κB target gene induction was augmented in RNF20^+/−^ relative to WT organoids ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). Likewise, peritoneal inflammatory leukocytes (mostly monocytes) and bone marrow-derived macrophages from RNF20^+/−^ mice, underexpressing *RNF20* ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F), displayed an augmented TNF-α response at both RNA ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}F) and secreted cytokine ([Figure 3](#fig3){ref-type="fig"}F) levels.

Thus, in non-cancerous epithelial cells, intestinal organoids, and innate immune cells, reduced RNF20/H2Bub1 augments the proinflammatory transcriptional response.

RNF20 Heterozygous Mice Are Prone to Severe Colonic Inflammation {#sec2.4}
----------------------------------------------------------------

Dextran sodium sulfate (DSS) is extensively used to study mouse colonic inflammation ([@bib10]). To explore the impact of RNF20 on inflammation in vivo, mice were exposed to 2% DSS (3 cycles, 5 days each; [Figure 4](#fig4){ref-type="fig"}A). Inflammation was assessed by colonoscopy, using a five-parameter scoring system ([@bib1]) as described ([@bib11]). By day 7, inflammation became significantly more severe in RNF20^+/−^ colons than in WT colons ([Figure 4](#fig4){ref-type="fig"}B). Although inflammation subsided partially from day 65 onward, it remained higher in the heterozygotes. Moreover, by day 26 RNF20^+/−^ mice displayed augmented splenomegaly ([Figure 4](#fig4){ref-type="fig"}C), and by day 65 they had shorter colons compared to WT mice ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}A); both features persisted till day 180 ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Concordantly, DSS-treated RNF20^+/−^ mice lost more weight than WT mice ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Thus, RNF20^+/−^ mice are prone to augmented acute and chronic inflammation.

RNF20^+/−^ mice express less RNF20 in all tissues. To assess the contribution of the bone marrow (BM)-derived compartment, we performed BM transplantation studies where BM of each genotype was transplanted into irradiated mice of each genotype. Reassuringly, WT mice reconstituted with WT BM were less inflamed than RNF20^+/−^ mice reconstituted with RNF20^+/−^ BM ([Figure 4](#fig4){ref-type="fig"}E). Interestingly, both WT mice reconstituted with RNF20^+/−^ BM and RNF20^+/−^ mice reconstituted with WT BM displayed intermediate inflammation, suggesting that both the intestinal epithelial compartment and the myeloid compartment contribute to the increased inflammation in RNF20^+/−^ mice, consistent with the augmented cytokine responses in both cell types in vitro ([Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}).

Remarkably, RNF20^+/−^ colons had compromised barrier function, resulting in increased fluorescence in the blood of mice force-fed dextran FITC ([Figure 4](#fig4){ref-type="fig"}F). This intestinal leakiness, perhaps due to reduced expression of tight junction genes (e.g., cingulin, [Figure S4](#mmc1){ref-type="supplementary-material"}E), may offer an additional explanation for the epithelial contribution to the augmented inflammation. Interestingly, c-Myc expression was elevated in RNF20^+/−^ colons ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

Although average *RNF20* mRNA levels in RNF20^+/−^ colons and lungs ([Figures S4](#mmc1){ref-type="supplementary-material"}F and S4G) was approximately half that of WT mice, it varied greatly among individual mice ([Figure 4](#fig4){ref-type="fig"}G). H2Bub1 correlated well with *RNF20* mRNA ([Figure S4](#mmc1){ref-type="supplementary-material"}H). Remarkably, regardless of genotype, *RNF20* mRNA levels (measured in the non-inflamed lungs) were strongly inversely correlated with colonic inflammatory score ([Figure 4](#fig4){ref-type="fig"}G), as seen also with interferon gamma (IFN-γ) secretion from colon slices at day 7, *MIP2* mRNA expression at day 26, and colon length and spleen weight at day 180 ([Figures S4](#mmc1){ref-type="supplementary-material"}I--S4L). This argues strongly that the increased inflammation in RNF20^+/−^ mice is indeed due to the actual downregulation of RNF20 (and presumably H2Bub1).

Increased MDSC Activation in RNF20^+/−^ Mice {#sec2.5}
--------------------------------------------

Under inflammatory conditions, immune cells infiltrate the colonic epithelium. Notably, immune patches composed mainly of T cells, B cells, and macrophages were more abundant in DSS-treated RNF20^+/−^ than in WT mice ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). RNF20^+/−^ mice displayed more infiltrating macrophages (F4/80 positive, [Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D), including M2 macrophages (CD206^+^, [Figure 4](#fig4){ref-type="fig"}H), as well as more T cells (CD3^+^, [Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F), at both day 26 and 65. Importantly, RNF20-deficient mice had more myeloid-derived suppressor cells (MDSCs), identified by IHC staining for CD11b^+^ and Gr1 ([Figure 4](#fig4){ref-type="fig"}I) and CD11b positivity by FACS ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Those MDSCs were more active, producing excessive ROS and nitric oxide ([Figure S5](#mmc1){ref-type="supplementary-material"}H) and overexpressing *Arginase 1* ([Figure S5](#mmc1){ref-type="supplementary-material"}I). Furthermore, T cell receptor ζ chain was downregulated in RNF20^+/−^ splenic T cells ([Figure S5](#mmc1){ref-type="supplementary-material"}J), indicative of impaired T cell function. CD3 epsilon was comparable in WT and RNF20^+/−^ mice ([Figure S5](#mmc1){ref-type="supplementary-material"}J), further arguing that the reduced T cell functionality in the latter is mediated by MDSCs. Importantly, RNF20^+/−^ MDSCs revealed a significantly greater capacity to downregulate ζ chain levels in co-incubated naive T cells ([Figure 4](#fig4){ref-type="fig"}J). Hence, reduced RNF20/H2Bub1 might promote immunosuppression via increased MDSC activation.

Elevated NF-κΒ Activity and DNA Damage in RNF20^+/−^ Mice {#sec2.6}
---------------------------------------------------------

Consistent with the enhanced NF-κB activation in cultured cells, inflamed colons of RNF20^+/−^ mice revealed stronger nuclear p65 staining than WT mice, while p50 exhibited an opposite trend ([Figure 5](#fig5){ref-type="fig"}A). Nuclear γ-H2AX foci, indicative of DNA damage, were more abundant in RNF20^+/−^ colons ([Figure 5](#fig5){ref-type="fig"}B), probably reflecting the combined effect of increased DNA-damaging ROS ([@bib48]) and compromised DNA double strand break repair ([@bib8], [@bib38], [@bib41]). Notably, despite the marked increase in apparent DNA damage, p53 was only mildly elevated ([Figure 5](#fig5){ref-type="fig"}B); p21, the canonical p53 target gene, was hardly induced at all. This suggests a compromised p53 response, probably due to p53 mRNA downregulation in RNF20^+/−^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}E). Thus, while RNF20^+/−^ colonocytes accumulate more DNA damage, their ability to mount a full DNA damage response is compromised, potentially exacerbating genomic instability.

RNF20^+/−^ Mice Are Predisposed to Inflammation-Associated Colorectal Tumors {#sec2.7}
----------------------------------------------------------------------------

Chronic colonic inflammation promotes colorectal cancer ([@bib56], [@bib58]). In the mouse, this is greatly enhanced by combining DSS with the chemical carcinogen azoxymethane (AOM) ([@bib61], [@bib55]). We therefore injected mice with AOM (1 μg/g body weight) 7 days prior to DSS exposure ([Figure 6](#fig6){ref-type="fig"}A). Colonoscopy revealed more polyps in RNF20^+/−^ mice than in WT mice ([Figure 6](#fig6){ref-type="fig"}B; representative images in [Figure S6](#mmc1){ref-type="supplementary-material"}A). Moreover, while RNF20^+/−^ adenomas often progressed to carcinoma by day 180, none did in WT mice ([Figure 6](#fig6){ref-type="fig"}C, DSS-AOM). Likewise, DSS alone elicited carcinomas by day 180 in several RNF20^+/−^ but no WT animals ([Figure 6](#fig6){ref-type="fig"}C, DSS). Some RNF20^+/−^ mice developed mucinous carcinoma with neoplastic glands invading the submucosa and penetrating the muscularis propria (T2), indicative of an aggressive course ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Hence, reduced RNF20 promotes both initiation and progression of inflammation-associated CRC in mice. Notably, the impact of partial RNF20 depletion on tumor progression was more pronounced than on inflammation. Thus, beyond augmented inflammation, additional effects of RNF20 shortage might also promote cancer in this setting.

While total H2B staining was similar in tumors and non-tumorous crypts ([Figure 6](#fig6){ref-type="fig"}D, left panels), polyps and carcinomas in both genotypes often displayed reduced H2Bub1 in both epithelial and stromal compartments ([Figures 6](#fig6){ref-type="fig"}D, 6E, and [S6](#mmc1){ref-type="supplementary-material"}C, arrows), implying that colorectal tumorigenesis is associated with further H2Bub1 decrease.

Lower H2Bub1 May Promote Human Ulcerative Colitis and Colorectal Cancer {#sec2.8}
-----------------------------------------------------------------------

To evaluate the human relevance of our findings, we analyzed a gene expression array including data from 27 healthy people, 35 UC patients with non-inflamed colons, and 38 UC patients with inflamed colons ([@bib50]). For patients sampled multiple times, mean values were used. Remarkably, UC colons had reduced *RNF20* and *RNF40* mRNA ([Figure 7](#fig7){ref-type="fig"}A). Moreover, *RNF20* and *RNF40* were inversely correlated with several inflammatory cytokine mRNAs, including *IL6* and *IL8* ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B; [Table S1](#mmc1){ref-type="supplementary-material"}), consistent with the notion that H2Bub1 downregulation drives chronic inflammation and NF-κB activation also in humans. In agreement, H2Bub1 was markedly reduced in IBD patient colonic epithelium, and to a lesser degree, also in the stromal compartment, relative to non-specific mild chronic colitis (NSC) ([Figures 7](#fig7){ref-type="fig"}B and 7C). This raises the intriguing possibility that constitutively reduced RNF20/RNF40, leading to partial H2Bub1 depletion, may predispose humans to particular chronic inflammatory diseases.

Mouse colonic tumors exhibited reduced H2Bub1 ([Figure 6](#fig6){ref-type="fig"}D). Consistent with earlier observations ([@bib59]), a similar pattern was revealed in human CRC tissue microarrays ([Figures 7](#fig7){ref-type="fig"}D and 7E) and colitis-associated cancer (CAC) samples ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Specifically, H2Bub1 in the cancer cells declined along disease progression ([Figures 7](#fig7){ref-type="fig"}F and [S7](#mmc1){ref-type="supplementary-material"}D). Interestingly, partial H2Bub1 downregulation was often seen also in the tumor stroma, although no further reduction occurred as cancer progressed ([Figures 7](#fig7){ref-type="fig"}D and 7F). Significantly, analysis of TCGA (<http://www.cbioportal.org/public-portal/>) colon adenocarcinoma gene expression data, comparing normal and tumor samples from the same patients, revealed lower *RNF20* and *RNF40* mRNA in the cancer tissue ([Figure 7](#fig7){ref-type="fig"}G). Thus, H2Bub1 is often reduced in human CRC, partly owing to compromised *RNF20/40* expression, corroborating the human relevance of our mouse model.

Discussion {#sec3}
==========

In cultured cells, TNF-α elicits a rapid transient decrease in global H2Bub1, preceding the induction of NF-κB target genes. RNF20 depletion enhances NF-κB-dependent transcription of specific cytokine genes, suggesting that TNF-α-induced H2Bub1 downregulation facilitates the ensuing NF-κB response. The subsequent recovery of H2Bub1 might serve to tune down the NF-kB response. Consequently, constitutively reduced H2Bub1 might hamper efficient shutoff, resulting in prolonged "leaky" NF-kB activation. Notably, although H2Bub1 is the most likely mediator of the effects of RNF20, a contribution of additional RNF20 substrates cannot be ruled out presently.

The abundance of H2Bub1 on chromatin can dictate selective binding of numerous transcription-associated factors ([@bib53]). By altering chromatin architecture ([@bib15]), H2Bub1 may favor binding of p50 homodimers over p50-p65 heterodimers or p65 homodimers. Notably, downregulation of RNF20 and H2Bub1 reduces the heterochromatin mark H3K9me3 in the promoter region of affected cytokine genes ([Figure 1](#fig1){ref-type="fig"}C) and enables efficient Pol II recruitment ([Figure 1](#fig1){ref-type="fig"}D). This might involve the histone H3K9 methyltransferase EHMT1, which interacts constitutively with p50 homodimers ([@bib13]). TNF-α-induced downregulation of H2Bub1 might also facilitate the binding of the transcription elongation factor TFIIS ([@bib52]). Lacking a functional TAD, p50 homodimers might repress NF-κB activity ([@bib23], [@bib29]), keeping cytokine genes off in the absence of activation signals. When encountering an activation signal, H2Bub1 levels rapidly decrease; we propose that this attenuates the association of p50 homodimers with chromatin, favoring recruitment of transactivation-competent p65-containing dimers. Interestingly, human tumors often underexpress p50, probably fostering cancer progression ([@bib31]).

The modular role of H2Bub1 is not limited to TNF-α. Indeed, H2Bub1 and RNF20 also affect the transcriptional response to EGF and IFN-γ ([@bib51], [@bib5]). H2Bub1 is more dynamic than other histone modifications ([@bib17]); hence, rapid alterations in H2Bub1 may guide changes in other histone modifications ([@bib64], [@bib40]).

RNF20^+/−^ mice display increased susceptibility to colonic inflammation and inflammation-associated cancer. Since RNF20^+/−^ mice are heterozygous in all tissues, the elevated inflammation may be due to H2Bub1-dependent changes not only in the gut epithelium but also in other host components such as immune cells, a notion supported by the enhanced TNF-α response of RNF20^+/−^ inflammatory leukocytes and macrophages ([Figures 3](#fig3){ref-type="fig"}E, 3F, and [S3](#mmc1){ref-type="supplementary-material"}F), as well as by the bone marrow chimera experiments. Furthermore, we cannot exclude RNF20/H2Bub1 effects on gut microflora.

Notably, *RNF20* mRNA levels varied greatly between individual mice ([Figure 4](#fig4){ref-type="fig"}G), and inflammation inversely correlated with *RNF20* mRNA irrespective of genotype. This raises the intriguing possibility that in humans, where inter-individual differences in H2Bub1 levels are likely broader than in inbred mice, such inherent differences might affect susceptibility to chronic inflammatory diseases. Indeed, human ulcerative colitis (UC) is significantly associated with reduced *RNF20/40* expression ([Figure 7](#fig7){ref-type="fig"}A), and lower *RNF20/40* correlates with augmented inflammatory cytokine expression in human CRC ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B; [Table S1](#mmc1){ref-type="supplementary-material"}).

Remarkably, both with DSS alone and with DSS+AOM, aggressive tumors were observed exclusively in RNF20^+/−^ but not WT mice ([Figure 6](#fig6){ref-type="fig"}C). Indeed, as in our mouse tumors, many human sporadic CRC tumors exhibit reduced H2Bub1 ([@bib59]), which declines as tumors progress ([Figures 7](#fig7){ref-type="fig"}D--7F). Reduced *RNF20* and *RNF40* mRNA in human CRC ([Figure 7](#fig7){ref-type="fig"}G) provides at least one plausible mechanistic explanation for the frequent depletion of H2Bub1. Conceivably, compromised H2Bub1 probably contributes to colorectal carcinogenesis by more than just augmenting inflammation. H2Bub1 facilitates DNA repair ([@bib38], [@bib41], [@bib54]); indeed, RNF20^+/−^ mice display elevated γ-H2AX ([Figure 5](#fig5){ref-type="fig"}B), suggesting exacerbated DNA damage. Furthermore, RNF20^+/−^ mice exhibit abundant M2 macrophages, providing a tumor supportive environment. Importantly, they display enhanced recruitment and augmented activation of MDSCs, which suppress anti-tumoral T cell activity and thereby facilitate tumor progression ([@bib28]). Such non-cell autonomous effects of reduced RNF20 might underpin the increased tumor progression in RNF20^+/−^ mice as well as the association between lower H2Bub1 and advanced human cancer.

Stem cells (SCs) typically display low H2Bub1, which increases markedly during SC differentiation and is required for their differentiation ([@bib16], [@bib27]). Hence, reduced H2Bub1 might also increase the tendency of colonic epithelial cells to adopt stem cell-like features. Of note, NF-κB has a crucial role in crypt stem cell expansion ([@bib39], [@bib49]). Intriguingly, like RNF20, the stem cell E3 ligase RNF43 has also been implicated in colonic tumor suppression ([@bib30]).

In sum, our study highlights non cell-autonomous functions of H2Bub1 and implies that low H2Bub1 favors inflammation and cancer. It remains to be determined whether, like in mice, also in humans inter-individual variations in constitutive H2Bub1 levels may be a risk factor for UC and CRC and perhaps additional inflammatory diseases and inflammation-associated cancers.

Experimental Procedures {#sec4}
=======================

Cell Culture and siRNA Transfections {#sec4.1}
------------------------------------

MCF10A cells were cultured at 37°C in DMEMF-12 medium (Biological Industries) supplemented with penicillin and streptomycin as well as 10 μg/ml insulin, 0.1 μg/ml cholera toxin, 0.5 μg/ml hydrocortisone, 5% heat-inactivated horse serum, and 10 ng/ml EGF. YAMC cells were cultured at 32°C in RPMI-1640 (Biological Industries) supplemented with penicillin and streptomycin and 10^−6^ M hydrocortisone, 10^−5^ M α-thioglycerol, 1 μg/ml insulin, 5 units/ml mouse INF-γ, and 5% fetal calf serum. Small intestine organoids were prepared as described ([@bib47]).

siRNA-mediated knockdown was with Dharmafect 1 reagent according to the manufacturer's protocol (Dharmacon RNAi technologies, Thermo Fisher Scientific). siRNA oligonucleotide SmartPools (siLacZ, siRNF20, si-p65, si-p50, siRNF40, and siRad6) were from Dharmacon. Final concentration of all siRNA oligonucleotides was 25 nM. TNF-α from R&D Systems was applied at a final concentration of 10 ng/ml. Cells were washed twice with cold PBS, harvested, centrifuged for 2 min at 4,000 RPM, and frozen at −80°C until lysis.

Mouse Handling {#sec4.2}
--------------

DSS treatment, colonoscopy, and analysis of mouse tissues were as described ([@bib11]). Azoxymethane (Wako Chemicals, 011-20171; 1 μg/g) was injected intraperitoneally (i.p.) 7 days prior to the first DSS treatment. For bone marrow (BM) transplantation, mice were irradiated with 950 rad and injected intravenously with 5 × 10^6^ BM-derived cells. Mice were then treated for 6 weeks with Ciproxin and subjected to DSS treatment. For intestinal permeability experiments mice were force fed by gavage with Dextran FITC (T7816, Sigma-Aldrich; 0.6 g/g). After 6 hr, mice were bled and blood fluorescence intensity was measured. Procedures involving animals conformed to institutional guidelines approved by the Animal Ethics Committee of the Weizmann Institute (IACUC 00800211-1).

Inflammation severity and polyps were scored by colonoscopy according to a previously published five- parameter scoring system ([@bib1]); data was analyzed with the R statistical analysis software, employing ANOVA. H&E slides of each mouse were analyzed by two independent pathologists, and tumors were scored according to their grade: low grade dysplasia (LGD), high grade dysplasia (HGD), carcinoma in situ (Tis), tumor invading the submucosa (T1), and tumor invading the muscularis propria (T2).

To obtain peritoneal inflammatory leukocytes, mice were injected i.p. with 4% thioglycolate. Four days later, leukocytes were collected from mouse peritoneum and plated in a tissue culture dish.

Human Ethical Issues {#sec4.3}
--------------------

Primary colon biopsies for IHC studies were obtained from Hebrew University-Hadassah Medical Center under approval by the Institutional Review Board (HMO-0145-13), verifying that informed consent is not required.
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![RNF20 Affects the Transcriptional Response of MCF10A Cells to TNF-α\
(A) MCF10A cells were treated with 10 ng/ml TNF-α for different durations. RNF20, H2B, H2Bub1, and GAPDH were assessed by western blot analysis. Band intensities were quantified and the RNF20/GAPDH and H2Bub1/H2B ratios calculated. Similar results were obtained in six independent experiments.\
(B) MCF10A cells were transfected with siRNA targeted against RNF20 or LacZ (control). 48 hours later, cells were treated with 10 ng/ml TNF-α for different durations. *IL8* and *IL6* hnRNA levels were determined by qRT-PCR, employing intron-derived primers. Values were normalized to *GAPDH* mRNA in the same sample. ^∗^p \< 0.05. Error bars, SD. Similar results were obtained in four independent experiments.\
(C) MCF10A cells transfected as in (B) were harvested and subjected to chromatin immunoprecipitation (ChIP) with H3 and H3K9me3 antibodies. Precipitated DNA was subjected to qRT-PCR analysis with primers spanning the κB site of the *IL8* and *CXCL1* genes, or *GAPDH*-derived primers as control. H3K9me3 values were normalized to H3 values. Error bars, SD. Similar results were obtained in three independent experiments.\
(D) MCF10A cells transfected as in (B) were subjected to ChIP with antibodies specific for serine 5-phosphorylated RNA Pol II. Precipitated DNA was subjected to qRT-PCR analysis with primers spanning the κB site of the indicated cytokine genes, and primers derived from a non-transcribed genomic region (con) or *GAPDH* as controls. Values were normalized to input. Error bars, SD. Similar results were obtained in three independent experiments.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![RNF20 Modulates NF-κB Chromatin Binding\
(A) MCF10A cells were transfected with siRNA targeted against LacZ (control) or RNF20 for 48 hr and treated with 10 ng/ml TNF-α for 30 min. Cells were subjected to ChIP analysis with p65-specific antibodies. Precipitated DNA was subjected to qRT-PCR with primers spanning the κB sites of the *IL8*, *CXCL1*, and *IL6* genes or *CDKN1A* (*p21*)-derived primers as control. Values were normalized to input. Error bars, SD. Similar results were obtained in five independent experiments.\
(B) MCF10A cells were transfected and analyzed as in (A), but employing p50-specific antibodies. Error bars, SD. Similar results were obtained in five independent experiments.\
(C) MCF10A cells were transfected and treated with TNF-α as in (A). Total chromatin was enriched as described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, and chromatin-associated RNF20, p50 and p65 was determined by western blot analysis. Numbers indicate relative intensities of the p50 and p65 bands after normalization to the corresponding H2B signal; ratios in the control (siLacZ) untreated sample were set as 1.0. Relative p65/p50 ratio was calculated accordingly. Similar results were obtained in three independent experiments.\
(D) MCF10A cells were transfected and treated as in (A). Sequential chromatin immunoprecipitation (Re-ChIP) was performed as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, employing p65 antibodies followed by p50 antibodies. qRT-PCR analysis was as in (A). Error bars, SD. Similar results were obtained in three independent experiments.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Reduced RNF20 Augments the TNF-α Response in Mouse Cells, Intestinal Organoids, and Peritoneal Inflammatory Leukocytes\
(A) YAMC (young adult mouse colonocytes) cells were transfected with siRNA targeted against *RNF20* or *LacZ* as control and either treated or not treated with 10 ng/ml TNF-α for 30 min. H2B and H2Bub1 levels were assessed by Western blot analysis. Similar results were obtained in five independent experiments.\
(B) YAMC cells were transfected as in (A). Forty-eight hours later, cells were treated with 10 ng/ml TNF-α for 1 hr. *IL6* and *KC* mRNA levels were determined by qRT-PCR, and normalized to β-*actin* mRNA in the same sample. ^∗^p \< 0.05. Error bars, SD. Similar results were obtained in five independent experiments.\
(C) Small intestine organoids from WT or RNF20^+/−^ mice were either treated or not treated with 10 ng/ml TNF-α for 30 min. H2B and H2Bub1 levels were assessed by western blot analysis. The H2B and H2Bub1 panels are from two separate gels loaded with identical aliquots of the same extract. Similar results were obtained in four independent experiments.\
(D) Small intestine organoids from WT or RNF20^+/−^ mice were treated with 10 ng/ml TNF-α for different durations. Cytokine mRNA levels were determined by qRT-PCR and normalized to β-*actin* mRNA in the same sample. ^∗^p \< 0.05, ^∗∗^p \< 0.01. Error bars, SE. The graph represents average of four independent experiments.\
(E) Mice were injected intraperitoneally with 4% thioglycolate. Four days later, peritoneal inflammatory leukocytes were collected and either treated or not treated with 10 ng/ml TNF-α for 30 min. Cytokine mRNA levels were determined by qRT-PCR and normalized to β-*actin* mRNA in the same sample. ^∗^p \< 0.05. Error bars, SD. Similar results were obtained in three independent experiments.\
(F) Mice were injected intraperitoneally with 4% thioglycolate. Four days later, peritoneal inflammatory leukocytes were removed and treated with 10 ng/ml TNF-α for different durations. Secreted cytokines were quantified by ELISA. Similar results were obtained in three independent experiments.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![RNF20^+/−^ Mice Are More Prone to Acute and Chronic Colonic Inflammation\
(A) Timeline of the chronic DSS protocol.\
(B) Eight-week-old male WT or RNF20^+/−^ mice weighing 22--28 g were treated with 2% DSS as outlined in (A). To monitor inflammation, mice were anesthetized with 10% xylene and 10% ketamine, and colonoscopies were performed as indicated. Inflammation scores were calculated as described in [Experimental Procedures](#sec4){ref-type="sec"}.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Error bars, SE. At least eight mice of each group were analyzed.\
(C) Spleens of either WT or RNF20^+/−^ mice were collected at day 26 and weighed. ^∗^p \< 0.05. n, number of mice per group. Error bars, SE.\
(D) WT and RNF20^+/−^ mice were sacrificed at day 65 and colon lengths were measured. ^∗∗^p \< 0.01. n, number of mice per group. Error bars, SE.\
(E) Six-week-old male mice were sub-lethally irradiated to deplete bone marrow (BM) cells, and injected with BM cells derived from either WT or RNF20^+/−^ mice. Mice were then treated with DSS as outlined in (A). Inflammation was monitored as in (B). ^∗^p \< 0.05, ^∗∗^p \< 0.01. Error bars, SE. At least six mice of each group were analyzed. The genotypes of the irradiated recipient mice and the donor BM are indicated without brackets and in brackets, respectively.\
(F) Non-treated WT and RNF20^+/−^ mice were force fed dextran-FITC by gavage. Fluorescence intensity in the blood was measured 6 hr later. Blank, background fluorescence in mice not injected with dextran-FITC. ^∗^p \< 0.05. Error bars, SE.\
(G) RNA was extracted from lungs of WT and RNF20^+/−^ mice as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. *RNF20* mRNA levels in lungs of individual mice were plotted against the corresponding colonoscopy scores. Spearman correlation coefficient = −0.775, ^∗∗∗^p \< 0.001.\
(H) Colons of DSS-treated RNF20^+/−^ and WT mice collected at day 26 were subjected to IHC staining for CD206. Lower panels show a higher magnification of the dashed area in upper panels. Arrowheads indicate positive nuclei. Lower magnification scale bars, 100 μm; higher magnification scale bars, 50 μm; bottom, quantification based on six WT mice and five RNF20^+/−^ mice; HPF, high power field. ^∗^p \< 0.05, ^∗∗^p \< 0.01. Error bars, SE.\
(I) Colons of DSS-treated WT and RNF20^+/−^ mice collected at day 26 were subjected to IHC staining for CD11b and Gr1. Insets: a higher magnification of the dashed area. Lower magnification scale bar, 100 μm; higher magnification scale bar, 50 μm; bottom, quantification based on six WT mice and five RNF20^+/−^ mice; HPF, high power field. ^∗∗^p \< 0.01. Error bars, SE.\
(J) Spleens of DSS-treated WT and RNF20^+/−^ mice were collected at day 26. MDSCs were isolated and incubated with naive T cells from spleens of untreated RNF20^+/−^ mice as described in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}, at the indicated MDSC:T cell ratio. Cells were then subjected to FACS-based analysis of CD247 (T cell receptor zeta chain) within CD3^+^ cells. ^∗∗^p \< 0.01. Error bars, SE.\
See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Increased NF-κB Activation and DNA Damage in RNF20^+/−^ Mice\
(A) Colons sections of DSS-treated WT and RNF20^+/−^ mice collected at day 26 were stained for p65 and p50. Arrowheads denote positive nuclei. Scale bar, 50 μm. LI%, labeling index. ^∗^p \< 0.05. Error bars, SE. Right panel: quantification based on five WT and six RNF20^+/−^ mice.\
(B) Colons of DSS-treated WT and RNF20^+/−^ mice collected at day 26 were subjected to IHC staining for γ-H2AX, p53 and p21. Arrowheads denote positive nuclei. Scale bar, 50 μm. LI%, labeling index. ^∗^p \< 0.05, ^∗∗^p \< 0.01. Error bars, SE. Right panel: quantification based on three WT and four RNF20^+/−^ mice.](gr5){#fig5}

![RNF20^+/−^ Mice Are Predisposed to Colonic Tumorigenesis\
(A) Timeline of the DSS-AOM protocol.\
(B) Eight-week-old male mice weighing 22--28 g were treated with 1 μg/g AOM plus 2% DSS as described in (A). Polyps were monitored by colonoscopy on the indicated days. ^∗^p \< 0.05. Error bars, SE.\
(C) Colons of WT and RNF20^+/−^ mice, treated as indicated at the bottom, were collected at day 180 and subjected to histopathological analysis. Bars depict the percentage of mice with the indicated lesions within a given treatment group; in mice with more than one type of lesion, only the most advanced lesion was considered. LGD, low grade dysplasia; HGD, high grade dysplasia; Tis, carcinoma in situ; T1, carcinoma invading the submucosa; T2, carcinoma invading the muscularis propria; n, number of mice per group.\
(D) Colons of DSS+AOM-treated mice of the indicated genotype were collected at day 65. Consecutive slides were stained for H2B and H2Bub1, respectively. N, normal tissue; T, tumor. Panels on the right show a higher magnification of the dashed areas in the left H2Bub1 panels. Scale bars, 200 μm for lower magnification, 25 μm for higher magnification. Lower panel: quantification based on eight WT and ten RNF20^+/−^ mice. ^∗∗∗^p \< 0.001. Error bars, SE.\
(E) Colons of DSS+AOM-treated mice of the indicated genotypes were collected at day 180. Polyps and adjacent normal tissue were extracted and subjected to western blot analysis for H2Bub1 and H2B.\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![Reduced *RNF20* and *RNF40* mRNA and H2Bub1 in Human Colonic Pathologies\
(A) Published microarray data ([@bib50]) was analyzed, comparing average *RNF20* and *RNF40* mRNA levels in colons of individuals with no colonic pathologies (Normal) to those of ulcerative colitis patients (UC), regardless of inflammation status. ^∗^p \< 0.05, ^∗∗^p \< 0.01. Error bars, SE.\
(B) Colon samples from 25 non-specific mild chronic colitis (non-specific colitis \[NSC\]) patients and 19 ulcerative colitis (UC) patients were stained for H2Bub1 or total H2B. Representative cases are shown. Insets: higher magnification of dashed area. Lower magnification scale bar, 100 μm; higher magnification scale bar, 25 μm.\
(C) IHC from (B) was quantified for relative H2Bub1 staining intensity in epithelium and stroma. ^∗∗∗^p \< 0.001. Error bars, SE.\
(D) A tissue microarray from 75 human CRC patients, classified using the tumor node metastasis (TNM) system, was stained for H2Bub1 and total H2B. Scale on upper right indicates relative H2Bub1 intensity (H2Bub1/H2B). TNM stages: I, carcinoma invading the submucosa; II, carcinoma invading the muscularis propria; III, carcinoma invading through the muscularis propria into the pericolorectal tissue.\
(E) Representative H2B and H2Bub1 staining of normal and cancerous human colonic tissue. Insets: higher magnification of dashed area. Lower magnification scale bar, 100 μm; higher magnification scale bar, 25 μm.\
(F) Quantification of the data in (D). ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.\
(G) *RNF20* and *RNF40* mRNA levels were compared between colorectal cancer (CRC) and corresponding normal colonic tissue, using the TCGA database (<http://www.cbioportal.org/public-portal/>). ^∗∗^p \< 0.01. Error bars, SE.\
See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
